Herpes Simplex Virus-2 is a sexually transmitted viral infection, which often produces painful sores, usually in the genital area. Once infected, an individual may carry the virus and be subject to recurrent bouts of infection. Some estimate that as many as 20 percent of the adult population in the United States has been exposed to the virus.
Hiding their DNA genome inside the nucleus of the infected cells, the herpesviruses establish a lifelong infection in humans. Not well defined stress conditions are known to wake up these parasites from their dormancy - the latent phase - and reactivate the production of new viral progeny, eventually causing cell death by lysis - the lytic phase.
The first national survey of skin infections among high school athletes has found that wrestlers have the highest number of infections, with football players coming in a distant second, according to researchers at the University of Colorado Anschutz Medical Campus.
A scientific collaboration between Envigo and the Department of Infectious Disease at the University of Gothenburg, Sweden has unveiled study findings into rat models and their susceptibility to intra-vaginal herpes simplex virus-2 (HSV-2) infection.
The U.S. Food and Drug Administration has approved a viral melanoma therapy that was the focus of a phase III clinical trial led by Rutgers Cancer Institute of New Jersey Associate Director for Clinical Science and Chief Surgical Officer Howard L. Kaufman, MD, FACS.
More than 3.7 billion people under the age of 50 – or 67% of the population – are infected with herpes simplex virus type 1 (HSV-1), according to the World Health Organization’s first global estimates of HSV-1 infection published today in the journal PLOS ONE.
The U.S. Food and Drug Administration today allowed marketing of the first cerebrospinal fluid (CSF) nucleic acid-based test for simultaneous detection of multiple pathogens that can cause central nervous system infections.
Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that its Focus Diagnostics products business has received FDA 510(k) clearance to add the genital swab claim to its Simplexa HSV 1 & 2 Direct molecular test on the Integrated Cycler.
A few years ago, Andrew Myers' laboratory discovered a new way to synthesize an important class of antibiotics that could one day tackle the toughest, most resistant infections.
Doctor Scott Mueller and colleagues from the University of Melbourne's Department of Microbiology and Immunology at the Doherty Institute used state-of-the-art microscopy to painstakingly capture images of the interactions of three crucial types of immune cells rallying to destroy herpes simplex virus.
There may be two new ways to fight AIDS -- using a heat shock protein or a small molecule - to attack fibrils in semen associated with the human immunodeficiency virus (HIV) during the initial phases of infection, according to new research from the Perelman School of Medicine at the University of Pennsylvania.
NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports that it is accelerating its HerpeCide drug development program.
The biologist Armelle Corpet and paleo-climatologist Anna Nele Meckler will receive the 2015 Marie Heim-Vögtlin (MHV) Prize. This distinction rewards their remarkable scientific work supported by a MHV grant. The prize will be bestowed on 23 September 2015 at the Swiss National Science Foundation.
Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas HSV 1 and 2 Test for the direct detection and differentiation of HSV-1 and HSV-2 DNA in anogenital specimens from symptomatic patients. With dual target detection and automation, the cobas HSV 1 and 2 Test provides laboratories with the capability to report up to 94 results in significantly less time than traditional methods and provides a simplified workflow for sample handling in the laboratory.
Roche announced today that the US Food and Drug Administration has provided 510(k) clearance for the cobas Cdiff Test to detect Clostridium difficile (C. difficile) in stool specimens.
NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, discusses the significance of the strong effectiveness demonstrated by its anti-viral drug candidates in a lethal animal model of dermal herpes infection.
Although super-resolution light microscopy has broken new ground in our understanding of subcellular structures and the movement of individual molecules within cells, its use to investigate virus particles is in its infancy...
St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.
Nobody likes getting the flu, but for some people, fluids and rest aren't enough. A small number of children who catch the influenza virus fall so ill they end up in the hospital — perhaps needing ventilators to breathe — even while their family and friends recover easily. New research by Rockefeller University scientists, published March 26 in Science, helps explain why: a rare genetic mutation.
The fight to treat cancer and eradicate tumors will likely benefit from a new set of treatments if early development phases continue to show promise, according to Kalorama Information. The healthcare market research publisher stated that gene therapies that are able to deliver genetic material to a specific cell population or tumor that will result in the destruction of the tumor.
Case Western Reserve researchers are part of an international team that has discovered that a common herpes drug reduces HIV-1 levels — even when patients do not have herpes.